Title page

Title: The impact of mental health and substance use issues on COVID-19 vaccine readiness: a cross sectional community-based survey in Ontario, Canada

Authors: Kamna Mehra MSc DNB,¹ Roula Markoulakis PhD,^{1,2} Sugy Kodeeswaran BSc MHSc,³ Donald A. Redelmeier MD MSc,^{4,5} Mark Sinyor MSc MD,^{6,7} James MacKillop,^{8,9} Amy Cheung MD,^{6,7} Emily E. Levitt BA,^{8,9} Tracey Addison BA BEd.,³ Anthony Levitt MD.^{3,7}

- 1. Family Navigation Project, Sunnybrook Research Institute, Toronto, Ontario
- 2. Department of Occupational Science and Occupational Therapy, University of Toronto, Toronto, Ontario
- 3. Family Navigation Project, Sunnybrook Health Sciences Centre, Toronto, Ontario
- 4. Evaluative Clinical Sciences, Sunnybrook Health Sciences Centre, Toronto, Ontario
- 5. Department of Medicine, University of Toronto, Toronto, Ontario
- 6. Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario
- 7. Department of Psychiatry, University of Toronto, Toronto, Ontario
- 8. Peter Boris Centre for Addictions Research, McMaster University, Hamilton, Ontario
- 9. St. Joseph's Healthcare Hamilton, Hamilton, Ontario

Corresponding authors contact details

Dr Anthony Levitt Anthony.Levitt@sunnybrook.ca

Funding statement

This study was funded by the Sunnybrook Foundation & Sunnybrook Research Institute, COVID-19 Research Initiative.

Competing interests

None

Abstract

Background: COVID-19 vaccines have been approved for use in Canada since December 2020. However, data about factors associated with vaccine hesitancy and the impact of mental health and/or substance use (MHSU) issues on vaccine uptake are currently not available. The goal of this study was to explore factors, particularly MHSU factors, that impact COVID-19 vaccination intentions in Ontario, Canada.

Methods: A community-based cross-sectional survey with recruitment based on age, gender, and geographical location (to ensure a representative population of Ontario), was conducted in February 2021. Multinomial logistic regression was used to test the relationship between COVID-19 vaccination status and plans and sociodemographic background, social support, anxiety about contracting COVID-19, and MHSU concerns.

Results: Of the total sample of 2528 respondents, 1932 (76.4%) were vaccine ready, 381 (15.1%) were hesitant, and 181 (7.1%) were resistant. Significant independent predictors of vaccine hesitancy compared with vaccine readiness included younger age (OR=2.11, 95%CI=1.62-2.74), female gender (OR=1.36, 95%CI=1.06-1.74), Black ethnicity (OR=2.11, 95%CI=1.19-3.75), lower education (OR=1.69, 95%CI=1.30-2.20), lower SES status (OR=.88, 95%CI=.84-.93), lower anxiety about self or someone close contracting COVID-19 (OR=2.06, 95%CI=1.50-2.82), and lower depression score (OR=.90, 95%CI=.82-.98). Significant independent predictors of vaccine resistance compared with readiness included younger age (OR=1.72, 95%CI=1.19-2.50), female gender (OR=1.57, 95%CI=.10-2.24), being married (OR=1.50, 95%CI=1.04-2.16), lower SES (OR=.80, 95%CI=.74-.86), lower satisfaction with social support (OR=.78, 95%CI=.70-.88), lower anxiety about contracting COVID-19 (OR=7.51, 95%CI=5.18-10.91), and lower depression score (OR=.85, 95%CI=.76-.96).

Interpretation: COVID-19 vaccination intention is affected by sociodemographic factors,

anxiety about contracting COVID-19, and select mental health issues.

Introduction

Identifying predictors of COVID-19 vaccination hesitancy and resistance is crucial to implementing a successful vaccination campaign. In April 2020, a study conducted in the United States by Fisher et al.¹ found younger age, Black race, lower education, and prior missed vaccinations were independent predictors of COVID-19 vaccination hesitancy. Similarly, a study conducted in the United Kingdom and Ireland found that age, gender, ethnicity, geographical location, socioeconomic status (SES), and political affiliation were associated with COVID-19 vaccination hesitancy.² A recent survey in Ontario, Canada,³ found 17.2% participants were unwilling to receive the COVID-19 vaccine, and that females and those with lower education were more likely to be unwilling.; however, data on the impact of MHSU issues on COVID-19 vaccination acceptance in Canada are currently unavailable.⁷ Compared with the general population, people living with mental health and substance use (MHSU) issues have been shown to be at higher risk of contracting, and to have higher morbidity and mortality from, COVID-19 infection.^{4,5} Adverse medical outcomes from contracting COVID-19 are more substantial for people with severe mental illness than for those with less severe mental illness.⁶ Thus, the goal of the current study was to understand the predictors of COVID-19 vaccination hesitancy and resistance in a representative population of the province of Ontario, Canada, with a focus on the impact of MHSU issues on these intentions.

Methods

Participants and Procedures

The current study involved a community-based, cross-sectional survey of 2528 Ontarians, age 18 years or older, recruited as a provincially representative sample through a respondent panel: Delvinia's AskingCanadians. Individuals registered with AskingCanadians were randomly

4

sent a unique survey link. Interlocking quotas, based on known age, gender, and regional population (Toronto, Southwestern, Eastern, Central, and Northern) proportions were used.^{6,7} The aim of the interlocking quotas for age and gender was to ensure provincial representativeness based on a difference less than five percentage points or within five percent of the mean. Although regional population quotas were utilized, lower density regions outside of the largest city, Toronto, were oversampled to ensure adequate sample across all five regions of Ontario, based on the power needed to detect the known prevalence of depression in each region, within a 5% margin of error.⁸

The study was approved by the Sunnybrook Health Sciences Centre Research Ethics Board. Participants gave informed consent prior to participating. The survey comprised 63 items and was open from February 22 to March 15, 2021. Of those participants who were eligible and provided consent, the survey completion rate was 79%.

Measures

COVID-19 vaccination. Participants were asked about COVID-19 vaccination intention with responses reflecting whether or not they planned to get COVID-19 vaccination once available/eligible, had received the first or both doses of the vaccination, had heard about the vaccination but were undecided, had heard about it and did not plan to be vaccinated, and had not heard about the vaccination.

Sociodemographic data and COVID-19 related information. Age, gender, ethnicity, geographical location, education level, marital status, SES,⁹ and living situation information was collected. Satisfaction with social support since the onset of the pandemic (e.g., friends, family, community, co-workers, pets, etc.) was assessed via seven-point bipolar Likert scale (1=extremely satisfied/7=extremely dissatisfied). COVID-19 exposure risk was assessed using

an original 12-item checklist, with responses reflecting higher risk (being tested and diagnosed with COVID-19, being told they had COVID-19 by a professional, someone they lived with diagnosed with COVID-19, someone else close to them diagnosed with COVID-19, someone close to them passed away as a result of COVID-19) and lower risk (suspecting they had COVID-19 but not diagnosed, tested for COVID-19 but negative, someone they lived with was tested for COVID-19, someone close to them was tested for COVID-19, self-quarantine due to travel, healthcare worker dealing with COVID-19 patients, confirmed COVID-19 cases at places they visit). Fear of self and/or someone close contracting COVID-19 was assessed on two separate items (but later grouped together for analysis) via five-point Likert scale (1=extremely worried/5=not worried at all).

MHSU concerns. The presence of mental health concerns was assessed by the American Psychiatric Association's Diagnostic Statistical Manual (DSM)-5 Self-Rated Level 1 Cross-Cutting Symptom Measure (CCSM), Adult version.¹⁰ This measure has good test-retest reliability and is clinically useful in Canadian samples.¹¹ The Cronbach's alpha, in the current study, for subscales with more than 1 item ranged from .69 to .85 and for the overall scale (20 items) was 0.94. Substance use was assessed by the World Health Organization Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST v3.0).¹² Substances assessed included tobacco, alcohol, cannabis, and opioids. This scale categorizes participants into low, moderate, and high risk categories for substance use disorder and has good to excellent internal validity.¹³

Statistical Analysis

Statistical analysis was conducted using SPSS 26.0. Vaccination intention was divided into those who: planned to receive the vaccination or had received the first/both doses (vaccine

ready), were undecided (vaccine hesitant), or did not plan to receive the vaccination (vaccine resistant). Univariate analyses were conducted using chi-square tests and ANOVA to compare vaccine ready, hesitant, and resistant based on sociodemographic variables, COVID-19-related variables, and MHSU variables. Multinomial logistic regression was then conducted to compare vaccine hesitant or resistant to vaccine ready participants. Variables included in the logistic regression were those that were significant in the univariate analyses. In the multinomial logistic regression which compared vaccine ready participants with both vaccine hesitant or resistant participants, the independent variables included were age (median split, since continuous variable did not have a linear relationship with its logit), gender (women vs. men), ethnicity (Non-Caucasian vs. Caucasian), geographical location (GTA vs. outside GTA), education (completed college/university vs. not completed college/university), marital status (married vs. unmarried), and anxiety about self and/or someone close contracting COVID-19 (not worried vs. worried, since the continuous variable did not have a linear relationship with its logit). Scores on the depression, anxiety, suicidal ideation, psychosis, and repetitive thoughts and behaviors subscales from the DSM-5 CCSM, social support, and SES since onset of pandemic were entered as continuous variables. Tobacco, cannabis, and opioid use were entered as categorical variables (no/low risk vs moderate/high risk).

Results

The mean age of the study sample was 48.26 years (within 5% of the provincial average age of adults 18 years or older of 48.14 years.)¹⁴ The gender distribution was 49.8% women and 48.9% men (within 5% of the provincial distribution of 51.2% women and 48.8% men.)¹⁵

Out of 2528 participants, 1819 (72.0%) planned to get COVID-19 vaccination when available to them, 58 (2.3%) had received the first dose of the vaccination, 55 (2.2%) had

received both the first and second dose of the vaccination, 381 (15.1%) had heard about the vaccination but were undecided, 181 (7.2%) had heard about it and did not plan to be vaccinated, and 34 (1.3%) had not heard about the vaccination.

Univariate tests for vaccination intention: Sociodemographic variables. Based on chi-square analysis, there was significant difference between vaccine ready, vaccine hesitant, and vaccine resistant participants based on sociodemographic variables (Table 1). Those who were younger than the median age of 47 years (χ^2 =50.751, p<.001), women (χ^2 =5.378, p=.020), unmarried (χ^2 =6.173, p=.013), or had not completed college/university (χ^2 =24.243, p<.001) were significantly more likely to be vaccine hesitant than vaccine ready. Those who were younger (χ^2 = 16.826, p<.001), living outside the Greater Toronto Area (GTA) (χ^2 = 6.078, p=.014), or had not completed college/university (χ^2 =10.665, p=.001) were significantly more likely to be vaccine ready. The ANOVA comparing SES since the onset of the pandemic across those who were vaccine ready (M=6.78, SD=2.269), vaccine hesitant (M=5.90, SD=2.381), and vaccine resistant (M=5.31, SD=2.682), was significant (F(49.888), df(2), p<.001). Post hoc tests, using LSD, revealed participants with lower SES were more likely to be vaccine hesitant (MD=.88, p<.001) and vaccine resistant (MD=1.46, p<.001) than vaccine ready.

Univariate tests for vaccination intention: COVID-19 related variables. Using

ANOVA, there was a significant difference in mean social support since pandemic onset across those who were vaccine ready (M=4.52, SD=1.502), vaccine hesitant (M=4.33, SD=1.487), and vaccine resistant (M=3.88, SD=1.618; F(16.440), df(2), p<.001). Post hoc testing (LSD) revealed that vaccine hesitant (MD=.194, p=.022) and vaccine resistant (MD=.644, p<.001) participants were less satisfied with social support as compared with vaccine ready participants. Those who

were vaccine hesitant (χ^2 =17.376, p<.001) and vaccine resistant (χ^2 =176.384, p<.001) were significantly more likely to be worried about self and/or someone close contracting COVID-19 (Table 2). There was no significant difference between vaccine hesitancy, resistance, and readiness based on risk of COVID-19 (Table 2).

Univariate tests for vaccination intention: Mental health issues. Using ANOVA, there were significant differences between the mean scores on depression, suicidal ideation, anxiety, psychosis, and repetitive thoughts and behaviors sub-scales based on vaccination intention (Table 3). Based on post-hoc LSD analysis, higher mean scores in depression (MD=-.25, p=0.040), anxiety (MD=-.61, p<.001), suicidal ideation (MD=-.16, p<.001), psychosis (MD=-.22, p=0.001), and repetitive thoughts and behaviors (MD=-.39, p<.001) were associated with vaccine hesitancy rather than vaccine readiness. Higher mean scores for anxiety (MD=-.48, p=.044), suicidal ideation (MD=-.20, p<.001), psychosis (MD=-.38, p<.001), and repetitive thoughts and behaviors (MD=-.51, p<.001) were also significantly associated with vaccine resistance rather than vaccine readiness.

Univariate tests for vaccination intention: Substance use issues. There was a significant difference between vaccine ready, hesitant, and resistant participants in the proportion with moderate/high risk for substance use disorder (Table 4). Those who were vaccine hesitant were significantly more likely to be associated with moderate/high risk of tobacco use disorder (χ^2 =6.513, p=.011), cannabis use disorder (χ^2 =6.679, p=.010), and opioid use disorder (χ^2 =4.871, p=.027) compared to vaccine ready; and vaccine resistance was significantly more likely to be associated with moderate/high risk of tobacco use disorder (χ^2 =8.906, p=.003), cannabis use disorder (χ^2 =9.926, p=.002), and opioid use disorder (χ^2 =13.532, p<.001) compared to vaccine readiness.

Multinomial logistic regression tests for vaccination intention. Multinomial logistic regression modelling (Table 5) revealed variables that independently and significantly predicted vaccine hesitancy rather than vaccine readiness were: younger age (OR=2.11, 95%CI=1.62-2.74), female gender (OR=1.36, 95%CI=1.06-1.74), Black ethnicity (OR=2.11, 95%CI=1.19-3.75), lower education (OR=1.69, 95%CI=1.30-2.19), lower SES (OR=.88, 95%CI=.84-.93), lower anxiety about contracting COVID-19 (OR=2.06, 95%CI=1.50-2.82), and lower depression score (OR=.90, 95%CI=.82-.98). Significant independent predictors of vaccine resistance rather than vaccine readiness included younger age (OR=1.72, 95%CI=1.19-2.50), female gender (OR=1.57, 95%CI=1.10-2.24), being married (OR=1.50, 95%CI=1.04-2.16), lower SES (OR=.80, 95%CI=.74-.86), lower satisfaction with social support (OR=.78, 95%CI=.70-.88), lower anxiety about contracting COVID-19 (OR=7.51, 95%CI=5.18-10.91), and lower depression score (OR=.85, 95%CI=.76-.96).

Interpretation

This study found that higher scores on the depression measure independently differentiated participants who were vaccine ready compared to those who were hesitant or resistant; a novel finding, to the best of our knowledge. Depressed participants may be more introspective or concerned with their health, leading to higher readiness for vaccination. Alternatively, participants with depression may see vaccination as a concrete way to remove stressors from their lives. In addition, depressed participants may experience cognitive distortions contributing to negative interpretations of the pandemic,¹⁶ contributing to vaccine readiness. A study conducted by Palgi et al.¹⁷ found that among those who had already received the first dose of the vaccination, vaccine hesitancy was related to higher levels of depression. Our results do not support that finding, which may reflect a difference in the sampling, the tools

used to assess mental health issues, or geographic or cultural differences. Additionally, in the current study, no other MHSU issues, including anxiety disorders, significantly differentiated those who were vaccine hesitant or resistant from those who were vaccine ready. This finding suggests it is not reasonable to ascribe vaccine hesitancy or resistance to any large degree to most MHSU issues. However, depression was found to be associated with vaccine readiness and this relationship warrants further exploration.

Age, gender, ethnicity, education, marital status, and SES were found to be significant independent predictors of vaccine hesitancy or resistance, with younger participants, females, and those who identified with lower SES since the onset of the pandemic significantly more likely to be vaccine hesitant and resistant, similar to previous studies in Canada and other countries.^{1–3,18} Lower level of education and identifying with Black ethnicity significantly distinguished between vaccine readiness and vaccine hesitancy, but not between vaccine readiness and resistance. Of note, marital status was the only other variable that distinguished the hesitant and resistant participants, such that unmarried participants were less likely to be vaccine resistant. Exploring the possible reasons for being undecided but not unwilling are out of the scope of the current study and have been explored in other studies.² Nonetheless, this finding might suggest that more intensive education and appropriate information targeting these groups may enhance the proportion of the population who might be vaccine ready in the future.

Those participants who were vaccine resistant were significantly less satisfied with their social support since the onset of the pandemic than those who were vaccine ready. It is possible that people with fewer social interactions and lower satisfaction with those interactions may have less communication about COVID-19 vaccination through friends, family members, co-workers, community groups, etc. and therefore less information about the potential benefits of

11

vaccination. Furthermore, people who are happy with their social interactions may have the desire to continue or to expand their interactions, leading them to be more receptive to vaccination. Similar to previous findings, participants who were vaccine ready were more worried about themselves or someone close to them contracting COVID-19.¹⁸ Thus, consistent with other evidence, relationships may play a crucial role in COVID-19 vaccination intention, in that those with close relationships may feel a sense of social duty or moral obligation to protect those around them,¹⁹ or the fear of contracting the COVID-19 infection may lend to vaccine readiness.^{18,20}

Limitations. This study was limited to Ontario, and may not be generalizable outside the province. Furthermore, the sample was randomly selected from participants registered with a respondent panel, and the survey was only available online and in the English language. Although this group may not be representative of the entire population of Ontario, the sample had similar characteristics to the population of Ontario.^{14,15} Moreover, the vaccine readiness of individuals of a small proportion of the population may change over time.²¹ This cross-sectional design was also only able to identify associations between variables, and did not allow us to determine whether these findings have been stable as the vaccine rollout has progressed. For example, the spread of the COVID-19 Delta variant, after the current survey was conducted, may affect vaccine readiness. While other studies have shown stability in vaccine readiness over time,^{22,23} study of factors influencing vaccine readiness over time is warranted. Furthermore, the DSM-5 CCSM has been validated for use as a screening questionnaire, and is not meant to reflect severity or diagnosis of mental illness. Nonetheless, the internal reliability of the severity measure was adequate based on the excellent Cronbach's alpha.

Conclusion

12

This study provides data to decision makers to take into account as they work to enhance vaccine uptake and to ensure that certain populations are provided targeted and helpful information to make an informed choice about COVID-19 vaccination.

Data access Data presented in this manuscript is available upon reasonable request.

Acknowledgements None

Conflict of interest None

Funding This study was funded by the Sunnybrook Foundation & Sunnybrook Research Institute, COVID-19 Research Initiative. MS is supported by Academic Scholar Awards from the Departments of Psychiatry at Sunnybrook Health Sciences Centre and the University of Toronto.

Supplemental material None

Table 1: Sociodemographic information of survey respondents, based on the likelihood of

getting COVID-19 vaccination

Sociodemographic variable	Vaccine	Vaccine	Vaccine	χ^2	р
	ready	hesitant	resistant		value
	n (%)	n (%)	n (%)		
Age (median split)					
- 47 years and younger	867 (44.9%)	247 (64.8%)	110 (60.8%)	61.382	<.001
- 48 years and older	1065 (55.1%)	134 (35.2%)	71 (39.2%)		
Gender*					
- Woman	938 (49.3%)	211 (55.8%)	98 (54.7%)	6.651	.036
- Man	965 (50.7%)	167 (44.2%)	81 (45.3%)		
Ethnicity					
- Black	48 (2.6%)	20 (5.5%)	7 (4.0%)	15.271	.018
- Asian	302 (16.2%)	71 (19.5%)	21 (12.1%)		
- Caucasian	1413 (75.9%)	254 (69.8%)	133 (76.9%)		
- Other	99 (5.3%)	19 (5.2%)	12 (6.9%)		
Geographical area					
- Greater Toronto Area	734 (38.0%)	156 (40.9%)	52 (28.7%)	7.968	.019
(GTA)					
- Outside GTA	1198 (62.0%)	225 (59.1%)	129 (71.3%)		
Marital status					
- Married/Common-law	1255 (65.0%)	222 (58.3%)	120 (66.3%)	6.621	.037
- Unmarried	677 (35.0%)	159 (41.7%)	61 (33.7%)		

Education					
- Completed	1462 (75.7%)	242 (63.5%)	117 (64.6%)	30.813	<.001
university/college					
- Did not complete	470 (24.3%)	139 (36.5%)	64 (35.4%)		
university/college					
Living situation					
- Living with family	1396 (72.3%)	289 (75.9%)	132 (72.9%)	2.082	.353
- Living	536 (27.7%)	92 (24.1%)	49 (27.1%)		
alone/roommate/group					
home/other					

Note: * = Only women and men were included in the analysis, other genders were excluded.

Table 2: COVID-19 related variables and likelihood of getting COVID-19 vaccination

COVID-19 related variable	Vaccine	Vaccine	Vaccine	χ^2	p value
	ready	ready hesitant			
	n (%)	n (%)	n (%)		
COVID-19 anxiety self or					
someone close					
- Worried	1704 (88.2%)	306 (80.3%)	93 (51.4%)	175.159	<.001
- Not worried	228 (11.8%)	75 (19.7%)	88 (48.6%)		
COVID-19 risk					
- High risk	323 (16.7%)	71 (18.6%)	23 (12.7%)	3.097	.213
- Low risk	1609 (83.3%)	310 (81.4%)	158 (87.3%)		

Mental health issues	th issues Vaccine Vaccine		Vaccine	F	df	p value
	ready	hesitant	resistant			
	M (SD)	M (SD)	M (SD)			
Depression	2.30 (2.11)	2.55 (2.23)	2.58 (2.27)	3.149	2	.043
Suicidal ideation	.24 (.68)	.40(.85)	.44 (.90)	12.317	2	<.001
Anxiety	3.00 (3.01)	3.61 (3.15)	3.48 (3.33)	7.594	2	.001
Psychosis	.38 (1.12)	.60 (1.39)	.76 (1.65)	12.209	2	<.001
Repetitive thoughts	1.21 (1.71)	1.60 (1.92)	1.72 (2.04)	12.973	2	<.001
and behaviors						

Table 3: Mental health issues and likelihood of getting COVID-19 vaccination

Table 4: Substance use issues and likelihood of getting COVID-19 vaccination

Substance use issues	Vaccine	Vaccine	Vaccine	χ^2	p value
	ready	hesitant	resistant		
	n (%)	n (%)	n (%)		
Tobacco Use					
- Moderate/high risk	339 (17.5%)	88 (23.1%)	48 (26.5%)	13.429	.001
- No/low risk	1593 (82.5%)	293 (76.9%)	133 (73.5%)		
Alcohol use					
- Moderate/high risk	385 (19.9%)	64 (16.8%)	44 (24.3%)	4.504	.105
- No/low risk	1547 (80.1%)	317 (83.2%)	137 (75.7%)		
Cannabis use					
- Moderate/high risk	253 (13.1%)	69 (18.1%)	39 (21.5%)	14.350	.001

- No/low risk	1679 (86.9%)	312 (81.9%)	142 (78.5%)		
Opioid use					
- Moderate/high risk	47 (2.4%)	17 (4.5%)	13 (7.2%) 168	15.317	<.001
- No/low risk	1885 (97.6%)	364 (95.5%)	(92.8%)		

Table 5: Multinomial logistic regression comparing vaccine ready to vaccine hesitant and

vaccine resistant

Variables	Predictor	Reference	Vaccine	hesitant v	vs. Vaccine	Vaccine resistant vs. Vaccine		
			ready			ready		
			р	OR	95% CI	р	OR	95% CI
Categorical								
variables								
Age	47 years or	48 years or older	<.001*	2.11	1.62-2.74	.004*	1.72	1.19-2.50
	younger							
Gender	Female	Male	.014*	1.36	1.06-1.74	.013*	1.57	1.10-2.24
Ethnicity	Black	Caucasian	.011*	2.11	1.19-3.75	.081	2.19	.91-5.28
	Asian		.548	1.11	.79-1.56	.642	.88	.50-1.53
	Other		.683	.89	.52-1.53	.932	.97	.46-2.03
Geographical	Outside GTA	GTA	.407	.90	.69-1.16	.187	1.31	.88-1.96
location								
Education	Did not complete	Completed	<.001*	1.69	1.30-2.20	.055	1.44	.99-2.08
	college/university	college/university						
Marital status	Married	Unmarried	.602	.94	.73-1.20	.031*	1.50	1.04-2.16

Worry about	Not worried	Worried	<.001*	2.06	1.50-2.82	<.001*	7.51	5.18-10.91
contracting								
COVID-19								
Tobacco use	No/low risk	Moderate/high risk	.167	.81	.60-1.09	.230	.77	.50-1.18
Cannabis use	No/low risk	Moderate/high risk	.451	.88	.62-1.24	.150	.71	.45-1.13
Opioid use	No/low risk	Moderate/high risk	.192	.66	.35-1.24	.303	.66	.30-1.46
Continuous								
variables								
SES since pand	lemic		<.001*	.88	.8493	<.001*	.80	.7486
Social support since pandemic		.182	.95	.87-1.03	<.001*	.78	.7088	
Depression		.013*	.90	.8298	.010*	.85	.7696	
Anxiety			.959	1.002	.94-1.07	.614	.98	.89-1.07
Suicidal ideation			.130	1.17	.96-1.42	.077	1.28	.97-1.68
Psychosis			.664	.97	.87-1.09	.285	1.09	.93-1.28
Repetitive thou	Repetitive thoughts and behaviors			1.09	.98-1.20	.206	1.10	.95-1.27

Note: * = Significance at the .05 level, Full model χ^2 (38) = 352.556, p < .001, Nagelkerke

 $R^2 = .186$

References

- Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. *Ann Intern Med*. 2020;173(12):964-973. doi:10.7326/M20-3569
- Murphy J, Vallières F, Bentall RP, et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. *Nat Commun.* 2021;12(1):1-15. doi:10.1038/s41467-020-20226-9
- Syan, Sabrina K.; Gohari, Mahmood, Levitt, Emily E.; Belisario, Kyla; Gillard, Jessica; Dejesus, Jane; Mackillop J. COVID-19 vaccine perceptions and differenced by sex, age, and education in 1367 community adults in Ontario. *Front Public Heal*. Published online 2021.
- Wang QQ, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. *World Psychiatry*. 2021;20(1):124-130. doi:10.1002/wps.20806
- Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. *Mol Psychiatry*. 2021;26(1):30-39. doi:10.1038/s41380-020-00880-7
- 6. Ontario Office of Economic Policy. Ontario Demographic Quarterly: Highlights of first quarter 2020.
- Ontario Ministry of Finance. Census 2001 Highlights: Factsheet 2: Age and Gender Profiles of Ontario. 2003.
- 8. Levitt AJ, Boyle MH, Joffe RT, Baumal Z. Estimated prevalence of the seasonal subtype of major depression in a Canadian community sample. *Can J Psychiatry*. 2000;45(7):650-

654. doi:10.1177/070674370004500708

- 9. Adler NE, Epel ES, Castellazzo G, Ickovics JR. Relationship of subjective and objective social status with psychological and physiological functioning: Preliminary data in healthy white women. *Heal Psychol.* 2000;19(6):586-592. doi:10.1037/0278-6133.19.6.586
- 10. Bastiaens L, Galus J. The DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure as a Screening Tool. *Psychiatr Q.* 2018;89(1):111-115. doi:10.1007/s11126-017-9518-7
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders* (*DSM-5*®). American Psychiatric Pub.; 2013.
- Ali R, Awwad E, Babor TF, et al. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Development, reliability and feasibility. *Addiction*. 2002;97(9):1183-1194. doi:10.1046/j.1360-0443.2002.00185.x
- Humeniuk R, Ali R, Babor TF, et al. Validation of the alcohol, smoking and substance involvement screening test (ASSIST). *Addiction*. 2008;103(6):1039-1047.
 doi:10.1111/j.1360-0443.2007.02114.x
- Statistics Canada. Table 17-10-0005-01 Population estimates on July 1st, by age and sex. doi:https://doi.org/10.25318/1710000501-eng
- Statistics Canada. Ontario [Province] and Canada [Country] (table). Census Profile. 2016 Census.
- Schudy A, Żurek K, Wiśniewska M, Piejka A, Gawęda Ł, Okruszek Ł. Mental Well-Being During Pandemic: The Role of Cognitive Biases and Emotion Regulation Strategies in Risk Perception and Affective Response to COVID-19. *Front Psychiatry*. 2020;11. doi:10.3389/fpsyt.2020.589973
- 17. Palgi Y, Bergman YS, Ben-David B, Bodner E. No psychological vaccination: Vaccine

hesitancy is associated with negative psychiatric outcomes among Israelis who received COVID-19 vaccination. *J Affect Disord*. 2021;287:352-353. doi:10.1016/j.jad.2021.03.064

- Dror AA, Eisenbach N, Taiber S, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol*. 2020;35(8):775-779. doi:10.1007/s10654-020-00671-y
- Manning M Lou, Gerolamo AM, Marino MA, Hanson-Zalot ME, Pogorzelska-Maziarz
 M. COVID-19 vaccination readiness among nurse faculty and student nurses. *Nurs Outlook*. Published online 2021. doi:10.1016/j.outlook.2021.01.019
- Willis DE, Andersen JA, Bryant-Moore K, et al. COVID-19 vaccine hesitancy: Race/ethnicity, trust, and fear. *Clin Transl Sci*. Published online 2021. doi:10.1111/cts.13077
- Fridman A, Gershon R, Gneezy A. COVID-19 and vaccine hesitancy: A longitudinal study. *PLoS One*. 2021;16(4 April). doi:10.1371/journal.pone.0250123
- Wang J, Lu X, Lai X, et al. The changing acceptance of COVID-19 vaccination in different epidemic phases in China: A longitudinal study. *Vaccines*. 2021;9(3):1-17. doi:10.3390/vaccines9030191
- 23. Williams L, Flowers P, McLeod J, Young D, Rollins L. Social patterning and stability of intention to accept a COVID-19 vaccine in scotland: Will those most at risk accept a vaccine? *Vaccines*. 2021;9(1):1-9. doi:10.3390/vaccines9010017